These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Multiple-dose study of imipenem/cilastatin in patients with end-stage renal disease undergoing long-term hemodialysis. Berman SJ; Sugihara JG; Nakamura JM; Kawahara KK; Wong EG; Musgrave JE; Wong LM; Siemsen AM Am J Med; 1985 Jun; 78(6A):113-6. PubMed ID: 3859209 [TBL] [Abstract][Full Text] [Related]
8. Using imipenem and cilastatin during continuous renal replacement therapy. Cotton A; Franklin BD; Brett S; Holmes A Pharm World Sci; 2005 Oct; 27(5):371-5. PubMed ID: 16341743 [TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of imipenem and cilastatin during continuous venovenous hemodialysis in patients who are critically ill. Hashimoto S; Honda M; Yamaguchi M; Sekimoto M; Tanaka Y ASAIO J; 1997; 43(1):84-8. PubMed ID: 9116359 [TBL] [Abstract][Full Text] [Related]
10. Single-dose kinetics of imipenem/cilastatin during continuous arteriovenous haemofiltration in intensive care patients. Keller E; Fecht H; Böhler J; Schollmeyer P Nephrol Dial Transplant; 1989; 4(7):640-5. PubMed ID: 2510062 [TBL] [Abstract][Full Text] [Related]
11. Clearance of imipenem/cilastatin in acute renal failure patients treated by continuous hemodiafiltration (CAVHD). Vos MC; Vincent HH; Yzerman EP Intensive Care Med; 1992; 18(5):282-5. PubMed ID: 1527259 [TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of imipenem/cilastatin sodium in children with peritonitis. Claesson G; Eriksson M; Rogers JD Pharmacol Toxicol; 1992 Aug; 71(2):103-6. PubMed ID: 1438026 [TBL] [Abstract][Full Text] [Related]
13. [Study of the intraperitoneal penetration of imipenem/cilastatin in acute peritonitis with perforation]. Pezé P; Mounier M; Cevallos R; Denis F Pathol Biol (Paris); 1990 Jun; 38(5 ( Pt 2)):504-7. PubMed ID: 2385446 [TBL] [Abstract][Full Text] [Related]
14. Comparison of imipenem pharmacokinetics in patients with acute or chronic renal failure treated with continuous hemofiltration. Mueller BA; Scarim SK; Macias WL Am J Kidney Dis; 1993 Feb; 21(2):172-9. PubMed ID: 8430678 [TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetics and pharmacodynamics of continuous versus short-term infusion of imipenem-cilastatin in critically ill patients in a randomized, controlled trial. Sakka SG; Glauner AK; Bulitta JB; Kinzig-Schippers M; Pfister W; Drusano GL; Sörgel F Antimicrob Agents Chemother; 2007 Sep; 51(9):3304-10. PubMed ID: 17620371 [TBL] [Abstract][Full Text] [Related]
16. The penetration of imipenem/cilastatin into ascitic fluid in patients with chronic liver disease. Rolando N; Wade JJ; Philpott-Howard JN; Casewell MW; Williams R J Antimicrob Chemother; 1994 Jan; 33(1):163-7. PubMed ID: 8157557 [No Abstract] [Full Text] [Related]
17. Pharmacokinetics of imipenem/cilastatin in neutropenic patients with haematological malignancies. Janmohamed RM; Leyland MJ; Kelly J; Farrell I J Antimicrob Chemother; 1990 Mar; 25(3):407-12. PubMed ID: 2338419 [TBL] [Abstract][Full Text] [Related]
18. [Clinical and pharmacokinetic study of imipenem/cilastatin in children and newborn infants]. Bégué P; Quinet B; Baron S; Challier P; Fontaine JL; Lasfargues G Pathol Biol (Paris); 1989 May; 37(5):485-90. PubMed ID: 2674874 [TBL] [Abstract][Full Text] [Related]
19. [Pharmacokinetic and clinical evaluation of imipenem/cilastatin sodium in neonates and premature infants. A study of imipenem/cilastatin sodium by a perinatal co-research group]. Fujii R; Sakata H; Inyaku F; Fujita K; Maruyama S; Yoshioka H; Hashira S; Tajima T; Nakazawa S; Sato H Jpn J Antibiot; 1989 Apr; 42(4):953-72. PubMed ID: 2671429 [TBL] [Abstract][Full Text] [Related]
20. Imipenem/cilastin dosage during acute renal failure and hemofiltration. Dehne MG; Kroh UF Intensive Care Med; 1995 Oct; 21(10):863. PubMed ID: 8557879 [No Abstract] [Full Text] [Related] [Next] [New Search]